ARWR 241220 19.00P (ARWR241220P19000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

ARWR241220P19000

Watchlist

0.45
-0.57-55.88%

15min DelayTrading Nov 26 10:27 ET

0.45High0.45Low

Intraday

5D
Daily

News

Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs
MT Newswires08:14 ET
Here Are the Major Earnings After the Close Today
Seeking Alpha51minutes ago
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
WSJ07:41 ET
Express News | Sarepta: Co Will Nominate & Arrowhead Will Deliver Ind-Ready Constructs for 6 Targets Across Skeletal Muscle, Cardiac, CNS
Reuters07:01 ET
Express News | Sarepta Therapeutics Inc - CEO Doug Ingram to Join Arrowhead Board
Reuters07:00 ET
Express News | Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement With Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical Sirna Programs
Reuters07:00 ET

Comments

Andrew Whiteside

Nov 22 09:29

$Arrowhead Pharmaceuticals (ARWR.US)$ $50

stockhub

Apr 7 11:23

Hope price action is consistent with result

Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals (ARWR.US)$

Mooers' Insights

Tonyco

Apr 6 22:01

$Arrowhead Pharmaceuticals (ARWR.US)$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?

Moomoo AI

Mar 8 05:54

The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.

We Think Shareholders May Want To Consider A Review Of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

zulia3003

Mar 7 11:34

$Arrowhead Pharmaceuticals (ARWR.US)$ why drop today?